Skip to menu Skip to content Skip to footer
Professor Hemamali Samaratunga
Professor

Hemamali Samaratunga

Email: 

Overview

Background

Hemamali Samaratunga MBBS (Hons) LRCP (London) MRCS (UK) FRCPA, FRCPath

  • Specialist Anatomical Pathologist, Managing Director, Aquesta Specialised Uropathology
  • Full Professor, University of Queensland Faculty of Medicine
  • Visiting Medical Officer, Greenslopes Private Hospital

Hemamali graduated with honours from the University of Sri Lanka, Colombo Medical School and completed Pathology specialty training in Queensland. She held a number of consultant posts in both hospital and private practice. In 2008 she established Aquesta Uropathology which now provides diagnostic uropathology services to the majority of urologists in Queensland and Northern New South Wales. In addition to this she maintains a large second opinion consultation practice with requests obtained from throughout Australia and from overseas.

She is active in Genitourinary Pathology research with collaborators in Australia, USA, Canada, Karolinska Institute in Sweden and the Wellington School of Medicine in New Zealand. She held the position of Secretary of the International Society of Urological Pathology from 2015 to 2019.

She was a contributor to the 2004, 2015 and 2022 World Health Organization (WHO) books on Classification of Tumours: Pathology and Genetics of Tumours of the Urinary and Male Reproductive System. She participated in the 2015 revision of the WHO Tumour Classification in Zurich, Switzerland (4th edition) as member, Prostate Tumour Panel. She was a representative of the Expert Groups formulating structured reporting protocols for the Royal College Pathologists of Australasia on kidney, testis and prostate cancer and is currently chairperson of the structured reporting protocols for Genitourinary cancer. She is also currently the Convener for the RCPA Uropathology Quality Assurance Program.

Qualifications

MBBS (HONS) LRCP (London) MRCS (UK) FRCPA FRCPath

Current UQ Appointments

Academic Title-Professor

Non-UQ Appointments

2008 - current: Specialist Anatomical Pathologist & Managing Director, Aquesta Specialized Uropathology

2015 - Current: Visiting Medical Officer, Greenslopes Private Hospital

2003 - 2021: Visiting Medical Officer, Princess Alexandra Hospital

June 2001 - Oct 2008: Specialist Anatomical Pathologist, Sullivan Nicolaides Pathology, Brisbane

1993 - 1997: Specialist Anatomical Pathologist, Royal Brisbane Hospital

1998 - 2001: Senior Anatomical Pathologist, North Brisbane Hospitals Board

Research Interests

  • Granular tumour necrosis
  • Diagnosis of limited adenocarcinoma on prostate needle biopsy
  • Ductal adenocarcinoma of prostate
  • Mucinous adenocarcinoma of prostate
  • Radical prostatectomy handling and reporting
  • Micropapillary urothelial cancer
  • Mimics of bladder cancer

Awards and other Esteem Indicators

2017 Admitted to Fellowship of the Royal College of Pathologists, London (FRC Path) for sustained excellence in published works

2022 Awarded the Grawitz Medal of the International Society of Urological Pathology for distinguished service to the discipline of Urological Pathology

2023 Author of the publication Percentage grade 4 tumour predicts outcome for prostate adenocarcinoma in needle biopsies from patients with advanced disease: Ten year data from the TROG 03.04 RADAR Trial. Pathology 54: 49- 54, awarded the prize of

Article of the Year by the Royal College of Pathologists of Australasia.

2024 Distinguished Fellowship Award of the Royal College Pathologists of Australasia

For distinguished service to the discipline of Urological Pathology

Keywords

Pathology, Genitourinary cancer, Prostate, Kidney, Urinary tract, Testis, Penis

Availability

Professor Hemamali Samaratunga is:
Available for supervision

Research impacts

She has over 320 scientific publications and has a Google Scholar H-index of 56 with 18150 citations. To date she has authored or co-authored 28 books, 21 book chapters and 274 peer-reviewed publications. Apart from her primary research activities Professor Samaratunga actively collaborates with other research groups and is a regular contributor - often as primary or senior author to international research consortia. One notable contribution has been her involvement in the development of artificial intelligence programs for the reporting of prostate cancer. In collaborative studies involving colleagues from the Netherlands, Sweden, Australia, New Zealand and the United States she was chosen to be one of three expert pathologists to review all cases, thus setting the gold standard for the diagnosis and grading of prostate cancer. These studies have been published in highly prestigious journals as noted in her CV. Importantly in comparative studies, the AI program informed by the findings of group of three pathologists that included Professor Samaratunga, outperformed all other AI programs.

Works

Search Professor Hemamali Samaratunga’s works on UQ eSpace

305 works between 1988 and 2025

121 - 140 of 305 works

2017

Journal Article

Prognostic significance and biopsy characteristics of prostate cancer with seminal vesicle invasion on radical prostatectomy: a nationwide population-based study

Kristiansen, Anna, Drevin, Linda, Delahunt, Brett, Samaratunga, Hemamali, Robinson, David, Franck Lissbrant, Ingela, Stattin, Pär and Egevad, Lars (2017). Prognostic significance and biopsy characteristics of prostate cancer with seminal vesicle invasion on radical prostatectomy: a nationwide population-based study. Pathology, 49 (7), 715-720. doi: 10.1016/j.pathol.2017.08.008

Prognostic significance and biopsy characteristics of prostate cancer with seminal vesicle invasion on radical prostatectomy: a nationwide population-based study

2017

Journal Article

The decline of medical publishing: the rise of the pseudo-journal

Delahunt, Brett, Samaratunga, Hemamali and Egevad, Lars (2017). The decline of medical publishing: the rise of the pseudo-journal. Pathology, 49 (7), 673-674. doi: 10.1016/j.pathol.2017.08.001

The decline of medical publishing: the rise of the pseudo-journal

2017

Journal Article

Pathology Imagebase-a reference image database for standardization of pathology

Egevad, Lars, Cheville, John, Evans, Andrew J., Hornblad, Jonas, Kench, James G., Kristiansen, Glen, Leite, Katia R. M., Magi-Galluzzi, Cristina, Pan, Chin-Chen, Samaratunga, Hemamali, Srigley, John R., True, Lawrence, Zhou, Ming, Clements, Mark and Delahunt, Brett (2017). Pathology Imagebase-a reference image database for standardization of pathology. Histopathology, 71 (5), 677-685. doi: 10.1111/his.13313

Pathology Imagebase-a reference image database for standardization of pathology

2017

Journal Article

Kallikrein-related peptidase 4 induces cancer-associated fibroblast features in prostate-derived stromal cells

Kryza, Thomas, Silva, Lakmali M., Bock, Nathalie, Fuhrman-Luck, Ruth, Stephens, Carson, Gao, Jin, Samaratunga, Hema, Lawrence, Mitchell, Hooper, John D., Dong, Ying, Risbridger, Gail and Clements, Judith A. (2017). Kallikrein-related peptidase 4 induces cancer-associated fibroblast features in prostate-derived stromal cells. Molecular Oncology, 11 (10), 1307-1329. doi: 10.1002/1878-0261.12075

Kallikrein-related peptidase 4 induces cancer-associated fibroblast features in prostate-derived stromal cells

2017

Journal Article

Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases

Samaratunga, Hemamali, Delahunt, Brett, Srigley, John R., Yaxley, John, Johannsen, Shulammite, Coughlin, Geoffrey, Gianduzzo, Troy, Kua, Boon, Patterson, Imogen, Nacey, John N. and Egevad, Lars (2017). Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases. Histopathology, 71 (4), 641-647. doi: 10.1111/his.13278

Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases

2017

Journal Article

Clear cell renal cell carcinoma: validation of World Health Organization/ International Society of Urological Pathology grading

Dagher, Julien, Delahunt, Brett, Rioux-Leclercq, Nathalie, Egevad, Lars, Srigley, John R, Coughlin, Geoffrey, Dunglinson, Nigel, Gianduzzo, Troy, Kua, Boon, Malone, Greg, Martin, Ben, Preston, John, Pokorny, Morgan, Wood, Simon, Yaxley, John and Samaratunga, Hemamali (2017). Clear cell renal cell carcinoma: validation of World Health Organization/ International Society of Urological Pathology grading. Histopathology, 71 (6), 918-925. doi: 10.1111/his.13311

Clear cell renal cell carcinoma: validation of World Health Organization/ International Society of Urological Pathology grading

2017

Journal Article

Long-term outcomes of high-dose-rate brachytherapy for intermediate- and high-risk prostate cancer with a median follow-up of 10 years

Yaxley, John W., Lah, Kevin, Yaxley, Julian P., Gardiner, Robert A., Samaratunga, Hema and MacKean, James (2017). Long-term outcomes of high-dose-rate brachytherapy for intermediate- and high-risk prostate cancer with a median follow-up of 10 years. BJU International, 120 (1), 56-60. doi: 10.1111/bju.13659

Long-term outcomes of high-dose-rate brachytherapy for intermediate- and high-risk prostate cancer with a median follow-up of 10 years

2017

Conference Publication

PIRADS 3 lesions characterised by mp-MRI of the prostate correspond with an intermediate to high risk of clinically significant prostate cancer on whole specimen histopathology - a retrospective review of 42 cases

Scott, Susan E., Gianduzzo, Troy, Coughlin, Geoff, Kua, Boon, Parkinson, Rob, Samaratunga, Hemamali and Yaxley, John (2017). PIRADS 3 lesions characterised by mp-MRI of the prostate correspond with an intermediate to high risk of clinically significant prostate cancer on whole specimen histopathology - a retrospective review of 42 cases. ANZUP Annual Scientific Meeting - The Art & Science of Best Practice, Melbourne, VIC Australia, 16–18 July 2017. Chichester, West Sussex United Kingdom: Wiley-Blackwell.

PIRADS 3 lesions characterised by mp-MRI of the prostate correspond with an intermediate to high risk of clinically significant prostate cancer on whole specimen histopathology - a retrospective review of 42 cases

2017

Journal Article

UICC drops the ball in the 8th edition TNM staging of urological cancers

Delahunt, Brett, Egevad, Lars, Samaratunga, Hemamali, Varma, Murali, Verrill, Clare, Cheville, John, Kristiansen, Glen, Corbishley, Catherine and Berney, Daniel M. (2017). UICC drops the ball in the 8th edition TNM staging of urological cancers. Histopathology, 71 (1), 5-11. doi: 10.1111/his.13200

UICC drops the ball in the 8th edition TNM staging of urological cancers

2017

Journal Article

Initial multicentre experience of 68gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited

Siriwardana, Amila, Thompson, James, van Leeuwen, Pim J., Doig, Shaela, Kalsbeek, Anton, Emmett, Louise, Delprado, Warick, Wong, David, Samaratunga, Hemamali, Haynes, Anne-Maree, Coughlin, Geoff and Stricker, Phillip (2017). Initial multicentre experience of 68gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. BJU International, 120 (5), 673-681. doi: 10.1111/bju.13919

Initial multicentre experience of 68gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited

2017

Conference Publication

Diagnostic potential of PSMA PET in advanced renal cell carcinoma

Nicholson, C., Joshi, A., Rhee, H., Tham, M., Thomas, P., Blazak, J., Samaratunga, H., Ng, K. L., Globe, G., Vela, I. and Wood, S. (2017). Diagnostic potential of PSMA PET in advanced renal cell carcinoma. 70th Annual Scientific Meeting of the Urological Society of Australia and New Zealand, Canberra, ACT Australia, 24-27 February 2017. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/bju.13750

Diagnostic potential of PSMA PET in advanced renal cell carcinoma

2017

Journal Article

Editorial comment to biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam

Egevad, Lars, Samaratunga, Hemamali and Delahunt, Brett (2017). Editorial comment to biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam. International Journal of Urology, 24 (4), 286-287. doi: 10.1111/iju.13305

Editorial comment to biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam

2017

Journal Article

Prostate cancer grading: a decade after the 2005 modified Gleason grading system

Delahunt, Brett, Grignon, David J., Samaratunga, Hemamali, Srigley, John R., Leite, Katia R. M., Kristiansen, Glen, Evans, Andrew J., Kench, James G. and Egevad, Lars (2017). Prostate cancer grading: a decade after the 2005 modified Gleason grading system. Archives of Pathology and Laboratory Medicine, 141 (2), 182-183. doi: 10.5858/arpa.2016-0300-LE

Prostate cancer grading: a decade after the 2005 modified Gleason grading system

2017

Conference Publication

Expression of prostate specific membrane antigen in clear cell renal cell carcinoma, neovasculature of tumour, and circulating tumour cells

Nicholson, C., Rhee, H., Ng, K. L., Tse, B. W., Yeh, M-C, Russell, P., Nelson, C., Thomas, P., Samaratunga, H., Vela, I., Gobe, G. and Wood, S. (2017). Expression of prostate specific membrane antigen in clear cell renal cell carcinoma, neovasculature of tumour, and circulating tumour cells. 70th Annual Scientific Meeting of the Urological Society of Australia and New Zealand, Canberra, ACT Australia, 24-27 February 2017. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/bju.13750

Expression of prostate specific membrane antigen in clear cell renal cell carcinoma, neovasculature of tumour, and circulating tumour cells

2016

Journal Article

Editorial statement on Gleason scoring for prostate cancer: in regard to Zietman et al

Egevad, Lars, Samaratunga, Hemamali, Srigley, John R. and Delahunt, Brett (2016). Editorial statement on Gleason scoring for prostate cancer: in regard to Zietman et al. International Journal of Radiation Oncology - Biology - Physics, 96 (5), 1126-1127. doi: 10.1016/j.ijrobp.2016.08.029

Editorial statement on Gleason scoring for prostate cancer: in regard to Zietman et al

2016

Journal Article

New Gleason grading system: statement from the editors of 6 journals

Egevad, Lars, Samaratunga, Hemamali, Srigley, John R. and Delahunt, Brett (2016). New Gleason grading system: statement from the editors of 6 journals. Urologic Oncology: Seminars and Original Investigations, 34 (11), 479-480. doi: 10.1016/j.urolonc.2016.07.003

New Gleason grading system: statement from the editors of 6 journals

2016

Journal Article

Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease

Rhee, Handoo, Ng, Keng Lim, Tse, Brian Wan-Chi, Yeh, Mei-Chun, Russell, Pamela J., Nelson, Colleen, Thomas, Paul, Samaratunga, Hemamali, Vela, Ian, Gobe, Glenda and Wood, Simon (2016). Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease. Pathology, 48 (6), 613-616. doi: 10.1016/j.pathol.2016.05.011

Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease

2016

Journal Article

One is the new six: the international society of urological pathology (ISUP) patient-focused approach to Gleason grading

Srigley, John R., Delahunt, Brett, Egevad, Lars, Samaratunga, Hemamali, Yaxley, John and Evans, Andrew J. (2016). One is the new six: the international society of urological pathology (ISUP) patient-focused approach to Gleason grading. Canadian Urological Association Journal, 10 (9-10), 339-341. doi: 10.5489/cuaj.4146

One is the new six: the international society of urological pathology (ISUP) patient-focused approach to Gleason grading

2016

Journal Article

Reply by the authors

Egevad, Lars, Samaratunga, Hemamali, Srigley, John R. and Delahunt, Brett (2016). Reply by the authors. Urology, 96, 179-180. doi: 10.1016/j.urology.2016.07.006

Reply by the authors

2016

Journal Article

Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study

Yaxley, John W., Coughlin, Geoffrey D., Chambers, Suzanne K., Occhipinti, Stefano, Samaratunga, Hema, Zajdlewicz, Leah, Dunglison, Nigel, Carter, Rob, Williams, Scott, Payton, Diane J., Perry-Keene, Joanna, Lavin, Martin F. and Gardiner, Robert A. (2016). Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. The Lancet, 388 (10049), 1057-1066. doi: 10.1016/S0140-6736(16)30592-X

Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study

Funding

Past funding

  • 2018 - 2022
    Utilisation of fresh human kidney tissue for research into kidney disease
    Metro South Hospital and Health Service
    Open grant
  • 2010 - 2011
    Towards Concurrent Imaging of Primary & Secondary Prostate Cancers
    Royal Brisbane & Women's Hospital Research Foundation
    Open grant
  • 2009 - 2010
    Molecular strategies for staging prostate cancer
    Cancer Council Queensland
    Open grant
  • 2005 - 2007
    Multiple Molecular Markers for Prostate Cancer Diagnosis from Enriched Cells from Ejaculate
    Queensland Cancer Fund
    Open grant

Supervision

Availability

Professor Hemamali Samaratunga is:
Available for supervision

Looking for a supervisor? Read our advice on how to choose a supervisor.

Media

Enquiries

For media enquiries about Professor Hemamali Samaratunga's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au